A5077217745- Mosquito-borne diseases and control
- Cancer therapeutics and mechanisms
- Tuberculosis Research and Epidemiology
- Insect Pest Control Strategies
- Antibiotics Pharmacokinetics and Efficacy
- Mycobacterium research and diagnosis
- Malaria Research and Control
- Pneumonia and Respiratory Infections
- Antimicrobial Resistance in Staphylococcus
- Synthesis and biological activity
- Pneumocystis jirovecii pneumonia detection and treatment
- Antibiotic Resistance in Bacteria
- Drug Solubulity and Delivery Systems
- ATP Synthase and ATPases Research
- Parvovirus B19 Infection Studies
- Microbial Natural Products and Biosynthesis
- Drug Transport and Resistance Mechanisms
- Cancer Genomics and Diagnostics
- Bioactive Compounds and Antitumor Agents
- Viral-associated cancers and disorders
- Bacterial Infections and Vaccines
- Click Chemistry and Applications
- Insect symbiosis and bacterial influences
- Viral Infections and Vectors
- Lung Cancer Treatments and Mutations
Daiichi Sankyo (India)
2016-2023
Sun Pharma Advanced Research (India)
2021
Sun Pharma (India)
2020
Cleveland Clinic
2013
Background Dengue, a mosquito-borne viral disease, poses significant global public health risk. In tropical countries such as India where periodic dengue outbreaks can be correlated to the high prevalence of mosquito vector, circulation all four viruses (DENVs) and population density, drug for is being increasingly recognized an unmet need. Methodology/Principal findings Using knowledge traditional Indian medicine, Ayurveda, we developed systematic bioassay-guided screening approach explore...
Dengue is a mosquito-borne viral disease with global prevalence. It caused by four closely-related dengue viruses (DENVs 1–4). A vaccine that can protect against all an unmet public health need. Live attenuated development efforts have encountered unexpected interactions between the viruses, raising safety concerns. This has emphasized need to explore non-replicating options. Virus-like particles (VLPs) which elicit robust immunity in absence of infection offer potential promise for...
Dengue is a serious public health concern worldwide, with ∼3 billion people at risk of contracting dengue virus (DENV) infections, some suffering severe consequences disease and leading to death. Currently, there no broad use vaccine or drug available for the prevention treatment dengue, which leaves only anti-mosquito strategies combat menace. The present study an extension our earlier aimed determining in vitro vivo protective effects plant-derived phytopharmaceutical dengue. In previous...
We screened 194 Mycobacterium tuberculosis strains isolated from (TB) patients in Delhi and neighboring regions India to identify the prevalence of extensive drug resistance (XDR) clinical isolates. Among these, 104 isolates were found be multidrug resistant (MDR), 6 identified as XDR isolates, which was later confirmed by antimicrobial susceptibility testing against respective screening panel. Genotyping carried out amplifying sequencing following genes: rpoB (rifampin), katG (isoniazid),...
AbstractRBx 8700, an investigational oxazolidinone, has excellent activity against respiratory pathogens. We evaluated the In Vitro minimum inhibitory concentration (MIC) and bactericidal of RBx 8700 Mycobacterium tuberculosis avium complex (MAC) isolates. had MIC 1 μg/ml M. isolates resistant to both isoniazid (INH) rifampicin (RIF), whereas its either INH or RIF was 0.5 μg/ml.Keywords: 8700oxazolidinonesM. tuberculosisMycobacteriatuberculosis
Aim: The development of a novel inhibitor targeting gyrase B and topoisomerase IV offers an opportunity to combat multidrug resistance. Methods: We investigated the activity RBx 10080758 against Gram-positive bacteria in vitro vivo. Results: showed potent 50% inhibitory concentration 0.13 μM 0.25 IV, respectively, exhibited strong whole-cell with MIC ranges 0.015–0.06 0.015–0.03 μg/ml Staphylococcus aureus Streptococcus pneumoniae, respectively. In rat thigh infection model...
Abstract Background Dengue is a serious public health concern worldwide, with ~3 billion people at risk of contracting dengue virus (DENV) infections. Currently, no effective vaccine or drug available for the prevention treatment dengue, which leaves only anti-mosquito strategies to combat this disease. The present study was initiated determine in-vitro and in vivo protective effects plant-derived phytopharmaceutical dengue. Methodology/Principal Findings In our previous report, we had...
The most common cause of a neck mass in young adults is hyperplastic lymphadenopathy consequent to infection and inflammation. Castleman's disease (CD), an unusual benign lymphoproliferative disorder, infrequently causes masses. It occurs unicentric (UCD) multicentric (MCD) forms associated with human immunodeficiency virus (HIV), herpes 8 (HHV-8), Kaposi's sarcoma. We present the third known association between MCD previous immune thrombocytopenia absence HIV HHV-8 review its other...
Background: Haemophilus influenzae causes community-acquired respiratory tract and invasive infections in humans. Resistance to macrolides fluoroquinolones is emerging H. limiting its therapeutic options. In the present study we demonstrated vitro vivo potential of this novel ketolide against influenzae. Methods & Materials: MIC fresh clinical isolates (n=145) (β- lactamase producer, non-producer strains standard ATCC quality control strains) from tertiary care centers India was evaluated...
Background: Rifampicin is known to degrade at the acidic pH of stomach, especially in presence isoniazid. Although isoniazid also degrades partially, its degradation reversible. Objective: Presently, we provide a proof fact that simultaneous oral administration rifampicin (RIF), upon incorporation into solid lipid nanoparticles (RIF-SLNs), with (INH) overcomes INH-induced and improves bioavailability rats. Methods: Solid RIF (RIF-SLNs) were prepared using novel patented method. The effect...
Abstract Development of a novel inhibitor targeting Gyrase B and Topoisomerase IV offers potential opportunity to combat the drug resistance. In present study, we extensively investigated efficacy RBx 10080758, fluorobenzothiazole, against skin respiratory infections caused by Staphylococci Streptococci in vitro vivo models. 10080758 showed potent IC 50 0.06 μM also exhibited strong whole cell activity with MIC ranges 0.015-0.06, 0.015-0.03, 0.008-0.03, 0.008-0.0.06, 0.015-0.06 μg/ml...